Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

February 9, 2021 Providence Cancer Institute of Oregon

Join Providence Cancer Institute and the Society for Immunotherapy of Cancer (SITC) on Thursday, April 8, 2021, for Advances in Cancer Immunotherapy™, a live free program featuring the latest clinical advancements in cancer immunotherapy and most recent FDA-approvals. This program is recommended for healthcare professionals in clinical settings, students, and patient advocates, and will feature leading authorities in tumor immunology and cancer immunotherapy from the Earle A. Chiles Research Institute, a division of Providence.

Highlights include:

• Interactive, virtual setting to connect with local faculty and organizers

• Learning how to treat patients with FDA-approved immunotherapies

• A deep dive into identifying and managing Immune-Related Adverse Events

• COVID-19 considerations from the speakers’ direct experience

• Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

Attendees will also have an opportunity to connect with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

Event Details:
Date: Thursday, April 8, 2021
Time: 3:00pm – 8:00pm PST

Organizers:

Amy Hartman, DNP, FNP-C, Providence Cancer Institute

Rachel Sanborn, MD, Earle A. Chiles Research Institute at Providence Cancer Institute

Sasha Stanton, MD, PhD, Earle A. Chiles Research Institute at Providence Cancer Institute

Register for free

To learn more, or to view the full program, please click here.

Welcome to your journey for creating a healthier you

Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

Previous Article

Next Article

Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

Previous Article

Next Article

Other content in this Stream

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

Growing the surgical oncology programs at Providence Cancer Institute is a testament to our commitment to providing research-focused, comprehensive services and improving outcomes for patients.

In recognition of National Social Work Month, Darlene Corral, LCSW, shares a little insight into the importance of oncology social workers.

In honor of National Nutrition Month® Alyssa George, MA, RDN, program manager at Oncology Nutrition, Providence Cancer Institute, talks about the important connection between cancer and nutrition.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.

The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).

Jamie Zilverberg, MSN, FNP, AOCNP, receives the prestigious 2024 Values in Action Award, the highest honor given at Providence St. Joseph Health.

In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.

Providence registered dietitian Christina Speaks, MS, RDN, LD, shares valuable information about food and common cancer myths.

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinicians at Providence Cancer Institute working to create a living drug for incurable cancers.

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.

Highlights from 2023 events, achievements and advancements at Providence Cancer Institute.

Providence hematology oncologist and outdoors enthusiast Eric C. Anderson, M.D., shares his love of the Pacific Northwest and his philosophy of care for patients.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.

SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.

Providence Cancer Institute lung cancer expert to present a virtual education talk on lung cancer screening, prevention and latest treatments.

Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.